High anticancer efficacy of L-proline-m-bis (2-chloroethyl) amino-L-phenylalanyl-L-norvaline ethyl ester hydrochloride (MF13) In Vivo

Anticancer Research

Volumn 21, Issue 3 B, 2001, Pages 1681-1689

  Jiang, J D ^a   Zhang, H ^a   Li, J N ^a   Roboz, J ^a   Qiao, W B ^a   Holland, J F ^a   Bekesi, G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer efficacy; Apoptosis; MF13; Toxicity; Tumor bearing mice

Indexed keywords

ANTINEOPLASTIC AGENT; MF 13; PROLINE 3 BIS(2 CHLOROETHYL)AMINOPHENYLALANYLNORVALINE ETHYL ESTER; SARCOLYSIN; TRIPEPTIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES CELL; BODY WEIGHT DISORDER; BONE MARROW TOXICITY; CANCER REGRESSION; CELL VIABILITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEMATOPOIESIS; LEUKEMIA; LIVER CELL CARCINOMA; LYMPHOMA; MALE; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; COLONIC NEOPLASMS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; LEUKEMIA L1210; MALE; MELPHALAN; MICE; MICE, INBRED C57BL; MICE, NUDE; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034906778     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. New synthesis L-m-sarcolysin and tritiated sarcolysin
2. Acid coupling and aminolytic TFA cleavages approaches in a new synthesis of an L-m-sarcolysin containing antitumor tripeptide ester
3. Study on the antitumor activity of p-di-(2-chloroethyl)-amino-phenyllalanine (sarcolysin)
4. Peptide-guided cancer drugs show promise in mice
5. Selective tumor apoptosis by MF13, L-proline-m-bis (2-chloroethyl) amino-L-phenylalanine-L-norvaline ethyl ester, a new sarcolysin containing tripeptide
6. Increased cancericidal activity of PTT119, a new synthetic bis-(2-chloroethyl) amino-L-phenylalanine derivative with carrier amino acids: I. In vitro cytotoxocity
7. Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts
8. Evaluation of p-F-Phe-m-bis-(2-chloroethyl) amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia
9. Role fpr c-myc in apoptotic cell death in T-cell hybridomas
10. Changes in nuclear chromatin related to apoptosis or necrosis induced by the DNA topoisomerase II inhibitor fostriecin in Molt-4 and HL-60 cells are revealed by altered DNA sensitivity to denaturation
11. Cancer treatment by targeted drug delivery, to tumor vasculature in a mouse model
12. Cytotoxicity, and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells
13. Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores
14. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted system, and intact cells
15. Current concepts of treatment in medical oncology: New anticancer drugs
16. Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT 1080
17. Antitumor imidazotetrazines. Part 37. Conjugation of the DNA major-groove alkylating imidazotetrazine mitozolomide to peptide modifs recognizing the tumor groove
18. Alkylating agents, antimetabolites, hormones, and other antiproliferative agents
19. Sequence selectivity, cross linking efficiency and cytotoxicity of DNA-targeted 4-anilinoquinoline aniline mustards
20. Relationship between DNA cross links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard
21. Pharmacogenomics: Translating functional genomics into rational therapeutics
22. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?